argenex (ARGX) to Release Earnings on Thursday

Key Points

• argenex will release Q1 2026 results before the market opens on Thursday, May 7, 2026 (call at 6:00 AM ET); analysts expect EPS of $5.41 and revenue of $1.3351 billion for the quarter.
• Wall Street consensus is a Moderate Buy with a $1,016.22 average price target (2 Strong Buy, 18 Buy, 4 Hold), and analysts forecast roughly $25 EPS this fiscal year and $32 EPS next year.
• Shares opened at $776.02, trade in a 12‑month range of $510.05–$934.62, and the company has a market cap of $48.26 billion with a PE ratio of 39.76.

argenex (NASDAQ:ARGX - Get Free Report) is expected to be releasing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect argenex to post earnings of $5.41 per share and revenue of $1.3351 billion for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 6:00 AM ET.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Saturday, February 14th. The company reported $8.02 earnings per share (EPS) for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, analysts expect argenex to post $25 EPS for the current fiscal year and $32 EPS for the next fiscal year.

argenex Price Performance

Shares of NASDAQ ARGX opened at $776.02 on Thursday. argenex has a 12-month low of $510.05 and a 12-month high of $934.62. The company has a market capitalization of $48.26 billion, a PE ratio of 39.76, a price-to-earnings-growth ratio of 1.29 and a beta of 0.46. The firm's 50-day moving average is $759.62 and its two-hundred day moving average is $818.38.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ARGX. Glj Research raised shares of argenex to a "strong-buy" rating in a report on Friday, April 3rd. Zacks Research raised shares of argenex from a "strong sell" rating to a "hold" rating in a research note on Friday, February 20th. Citizens Jmp boosted their target price on shares of argenex from $925.00 to $944.00 and gave the company a "market outperform" rating in a research note on Friday, February 27th. Weiss Ratings reissued a "hold (c)" rating on shares of argenex in a research note on Monday, April 20th. Finally, Truist Financial boosted their target price on shares of argenex from $950.00 to $1,030.00 and gave the company a "buy" rating in a research note on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,016.22.

Institutional Investors Weigh In On argenex

Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC purchased a new stake in shares of argenex in the third quarter valued at $201,000. Diversify Advisory Services LLC purchased a new stake in shares of argenex in the third quarter valued at $195,000. Quantbot Technologies LP grew its position in shares of argenex by 120.1% in the second quarter. Quantbot Technologies LP now owns 306 shares of the company's stock valued at $169,000 after purchasing an additional 167 shares during the period. CIBC Private Wealth Group LLC grew its position in shares of argenex by 421.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 198 shares of the company's stock valued at $167,000 after purchasing an additional 160 shares during the period. Finally, Arax Advisory Partners grew its position in shares of argenex by 134.8% in the fourth quarter. Arax Advisory Partners now owns 155 shares of the company's stock valued at $130,000 after purchasing an additional 89 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenex Company Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.